Fabrice Branle

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari et al. · The Lancet · 2017 · 1.2K citations

Medicine, Oncology, Pharmacology +14

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2

Lucio Crinò, Myung‐Ju Ahn, Filippo de Marinis et al. · Journal of Clinical Oncology · 2016 · 351 citations · Full text

Medicine, Oncology, Pharmacology +17

Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy

Fabrice Branle, Florence Lefranc, Isabelle Camby et al. · Cancer · 2002 · 107 citations · Full text

Medicine, Neuroscience, Oncology +15

Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)

Guillaume Canaud, Juan Carlos López‐Gutiérrez, Alan D. Irvine et al. · Genetics in Medicine · 2023 · 92 citations · Full text

Medicine, Oncology, Pharmacology +7

ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).

Enriqueta Felip, Sergey Orlov, Keunchil Park et al. · Journal of Clinical Oncology · 2015 · 78 citations

Medicine, Oncology, Pharmacology +13